Small molecules are powerful tools for investigating protein function and can serve as leads for new therapeutics. Most human proteins, however, lack small-molecule ligands, and entire protein classes are considered 'undruggable' 1,2 . Fragment-based ligand discovery can identify small-molecule probes for proteins that have proven difficult to target using high-throughput screening of complex compound libraries 1,3 . Although reversibly binding ligands are commonly pursued, covalent fragments provide an alternative route to small-molecule probes 4-10 , including those that can access regions of proteins that are difficult to target through binding affinity alone 5,10,11 . Here we report a quantitative analysis of cysteinereactive small-molecule fragments screened against thousands of proteins in human proteomes and cells. Covalent ligands were identified for >700 cysteines found in both druggable proteins and proteins deficient in chemical probes, including transcription factors, adaptor/scaffolding proteins, and uncharacterized proteins. Among the atypical ligand-protein interactions discovered were compounds that react preferentially with pro-(inactive) caspases. We used these ligands to distinguish extrinsic apoptosis pathways in human cell lines versus primary human T cells, showing that the former is largely mediated by caspase-8 while the latter depends on both caspase-8 and -10. Fragment-based covalent ligand discovery provides a greatly expanded portrait of the ligandable proteome and furnishes compounds that can illuminate protein functions in native biological systems.
spectrometry (LC-MS). Quantification of MS1 chromatographic peak ratios for peptide pairs identifies fragment-competed Cys residues as those displaying high competition ratios, or R values, in DMSO/ fragment comparisons.
We constructed a fragment library predominantly containing chloroacetamide or acrylamide electrophiles ( Fig. 1b and Extended Data Fig. 1 ), which are well-characterized cysteine-reactive groups 10, [15] [16] [17] [18] . These electrophiles were appended to structurally diverse smallmolecule recognition (or binding) elements to create library members 1 Department of Chemical Physiology, The Scripps Research Institute. La Jolla, California 92307, USA. 2 Figure 1 | Proteome-wide screening of covalent fragments. a, General protocol for competitive isoTOP-ABPP. Competition ratios, or R values, are measured by dividing the MS1 ion peaks for IA-alkyne (1)-labelled peptides in DMSO-treated (heavy, blue) versus fragmenttreated (light, red) samples. LC/LC-MS/MS, multidimensional liquid chromatography-tandem mass spectrometry. b, General structure of electrophilic fragment library, in which the reactive (electrophilic) and binding groups are coloured green and black, respectively. c, Competitive isoTOP-ABPP analysis of the MDA-MB-231 cell proteome pre-treated with the electrophilic 3,5-di(trifluoromethyl)aniline chloroacetamide 3 and acrylamide 14 fragments, along with the non-electrophilic acetamide analogue 17 (500 μ M each). Proteomic reactivity values, or liganded cysteine rates, for fragments were calculated as the percentage of total cysteines with R values ≥ 4 in DMSO/fragment (heavy/light) comparisons. d, Representative MS1 peptide ion chromatograms from competitive isoTOP-ABPP experiments marking liganded cysteines selectively targeted by one of three fragments, 3, 14 and 23.
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with an average molecular weight of 284 Da. Since our goal was to probe the ligandability of cysteines in the human proteome, we screened the electrophile library at a high concentration (500 μ M) similar to the compound concentrations used in FBLD experiments 3 . A subset of the fragment library was initially assayed by competitive profiling in a human MDA-MB-231 breast cancer cell line proteome using IA-rhodamine probe 16, which permitted SDS-polyacrylamide gel electrophoresis (SDS-PAGE) detection of cysteine reactivity events. This experiment identified several proteins that showed reductions in IA-rhodamine labelling in the presence of one or more fragments (Extended Data Fig. 2a ).
We then used competitive isoTOP-ABPP to globally map human proteins and the cysteine residues within these proteins that are targeted by fragment electrophiles. Each fragment was tested against two human cancer cell proteomes (MDA-MB-231 and Ramos cells), and most fragments were screened in duplicate against at least one of these proteomes. On average, 927 cysteines were quantified per data set, and we required that individual cysteines were quantified in at least three data sets for interpretation. On the basis of these criteria, ~ 6,150 cysteines from ~ 2,900 proteins were quantified in aggregate across all data sets with an average quantification frequency of 22 data sets per cysteine (Extended Data Fig. 2b ). Fragment-competed cysteine residues, or 'liganded' cysteines, were defined as those showing ≥ 75% reductions in IA-alkyne labelling (R values ≥ 4 ). To minimize the potential for false positives, only cysteines that showed R values ≥ 4 in two or more data sets and met additional criteria for data quality control (see Supplementary Information) were considered as targets of the fragment electrophiles. The proteomic reactivity values, or liganded cysteine rates, of individual fragments were then calculated as the percentage of liganded per total quantified cysteines in isoTOP-ABPP experiments performed on that fragment.
Most fragment electrophiles showed a tempered reactivity across the human proteome, with a median liganded cysteine rate of 3.8% for the library (Extended Data Fig. 2c ). Substantial differences in reactivity were observed, however, with individual electrophiles showing liganded cysteine rates of < 0.1% and others displaying rates > 15% (Extended Data Fig. 2c ). A subset of fragments was also screened at lower concentrations (25-50 μ M), which confirmed that their proteomic reactivities were concentration-dependent (Extended Data Fig. 2d ). The relative reactivity of fragment electrophiles was similar in MDA-MB-231 and Ramos cell proteomes (Extended Data Fig. 2e ), indicating that this parameter is an intrinsic property of the compounds. Fragments also showed consistent reactivity profiles when assayed in biological replicate experiments (Extended Data Fig. 2f ). We found that the proteomic reactivity of fragment electrophiles was only marginally correlated with their glutathione adduction potential, which is a commonly used surrogate assay for measurements of proteinaceous cysteine reactivity 19 (Extended Data Fig. 2g ). We attribute these differences to the impact of the recognition element of fragment electrophiles on their interactions and reactivity with proteins.
A comparison of fragments 3, 14, 17, and 23-26 provided insights into the relative proteomic reactivity of different electrophilic groups coupled to a common recognition element (3,5-bis(trifluoromethyl) phenyl group). Chloroacetamide 3 exhibited greater reactivity than acrylamide 14 (Fig. 1c ), with cyanoacrylamide 23, but not more sterically congested electrophiles (24) (25) (26) exhibiting similar reactivity to 14 (Extended Data Fig. 2h ). Importantly, the non-electrophilic acetamide control fragment 17 showed negligible activity in competitive isoTOP-ABPP experiments (Fig. 1c) , indicating that the vast majority of detected fragment-cysteine interactions reflected covalent reactions versus non-covalent binding events. Also in support of this conclusion, 'clickable' alkyne analogues of 3 and 14 (compounds 19 and 18, respectively) exhibited different concentration-dependent proteome labelling profiles (19 > 18; Extended Data Fig. 2i ) that mirrored the respective liganded cysteine rates of 3 and 14 determined by iso-TOP-ABPP (3 > 14; Fig. 1c ). Despite the greater overall proteomic reactivity of 3 relative to 14 and 23, we found clear examples of cysteines that were preferentially liganded by the latter fragments ( Fig. 1d and Supplementary Table 1 ).
Across all isoTOP-ABPP data sets combined, 758 liganded cysteines were identified on 637 distinct proteins, which corresponded to ~ 12% and 22% of the total quantified cysteines and proteins, respectively ( Fig. 2a and Supplementary Table 1 ). Only a modest fraction of the proteins harbouring liganded cysteines were found in the DrugBank database (14%; Fig. 2b ), indicating that the fragment electrophiles targeted many proteins that lack small-molecule probes. Among protein targets with known covalent ligands, the fragment electrophiles frequently targeted the same cysteine residues as these known ligands (Extended Data Table 1a ). For one of these targets-the protein kinase BTK-we confirmed that interaction with the drug ibrutinib could be detected by isoTOP-ABPP, which also identified a known ibrutinib off target-MAP2K7 (ref. 20)-in Ramos cell lysates (Extended Data Fig. 3a ).
DrugBank proteins with liganded cysteines mostly originated from classes that are regarded as druggable, including enzymes, channels and transporters ( Fig. 2c ). Non-DrugBank proteins with liganded cysteines, on the other hand, showed a broader class distribution that included proteins, such as transcription factors and adaptor/scaffolding proteins, which are considered challenging to target with small-molecule ligands ( Fig. 2c ). We previously found that active-site and redox-active cysteines show, in general, greater intrinsic reactivity (as measured with the IA-alkyne probe) compared with other cysteines 12 . While this heightened reactivity appears to be a contributory factor to the ligandability of cysteines, as reflected in the high proportion of hyperreactive (and active-site and redox-active) cysteines discovered as targets of fragment electrophiles, liganded cysteines were also well represented Letter reSeArCH across a broad range of intrinsic reactivities and included many nonactive residues ( Fig. 2d , Extended Data Fig. 3b , c and Supplementary Discussion). Finally, most proteins were found to harbour a single liganded cysteine among the several cysteines that were, on average, quantified per protein by isoTOP-ABPP (Extended Data Fig. 3d , e and Supplementary Discussion).
Liganded cysteines, including those found in active and nonactive sites of proteins, displayed strikingly distinct structure-activity relationships (SARs) with the fragment electrophile library (Fig. 3a , Extended Data Fig. 3f -l, Supplementary Table 1 and Supplementary Discussion). We also found that, for the majority of liganded cysteines (> 60%), electrophile (IA-alkyne or fragment) reactivity was blocked by heat denaturation of the proteome, while only a modest fraction of unliganded cysteines (~ 20%) showed decreased IA-alkyne labelling after heat denaturation (Extended Data Fig. 3m , n and Supplementary Discussion). These results indicate that the ligand-cysteine interactions are, in general, specific, in that they depend on both the binding groups of ligands and structured sites in proteins (see Supplementary Discussion).
We next asked whether docking could predict sites of fragment electrophile reactivity. Covalent docking programs have recently been introduced to discover ligands that target pre-specified cysteines in proteins 21 ; here, however, we aimed to assess computationally the relative ligandability of all cysteines within a protein and match these outputs to the data acquired by isoTOP-ABPP (see Supplementary Discussion). The ranking of our computational predictions matched the experimental data for the majority of proteins investigated (that is, cases in which the top predicted ligandable cysteine matched the liganded cysteine determined by isoTOP-ABPP) (Fig. 3b , c and Extended Data Table 2 ). We also found that cysteines predicted to be ligandable were much more likely to have been detected by isoTOP-ABPP and exhibit heat-sensitive IA-alkyne reactivity (Extended Data Fig. 3o , p and Extended Data Table 2 ). These results indicate that reactive docking can provide a good overall prediction of the ligandability of cysteines.
To determine the functional impact of ligand-cysteine interactions mapped by isoTOP-ABPP, we initially selected two enzymes-the protein methyltransferase PRMT1 and the MAP3 kinase MLTK (also known as ZAK)-that possessed liganded cysteines with previously demonstrated activities 12, 13 . Our findings confirmed that the fragment electrophiles targeting PRMT1 and MLTK inhibited these enzymes (Extended Data Fig. 4a 
and Supplementary Discussion). We next evaluated proteins that possess previously uncharacterized liganded cysteines, including the nucleotide biosynthetic enzyme IMPDH2 and p53-induced phosphatase TIGAR (p53 also known as TP53). In both cases, we found that ligand-cysteine interactions affected specific functions of these proteins: regulatory nucleotide binding and catalytic activity, respectively (Extended Data Fig. 5a -g (IMPDH2), Extended Data Fig. 5h -n (TIGAR) and Supplementary Discussion).
Competitive isoTOP-ABPP experiments identified distinct subsets of ligands that targeted a conserved cysteine in isocitrate dehydrogenases 1 (IDH1) and 2 (IDH2) (C269 and C308, respectively; Supplementary  Table 1 ). IDH1 and IDH2 are mutated in a number of human cancers to produce enzyme variants with a neomorphic catalytic activity that converts isocitrate to the oncometabolite 2-hydroxyglutarate (2-HG) 22 . Reversible inhibitors selective for mutant forms of IDH1 and IDH2 have been developed and are under clinical investigation for cancer treatment 22 . The liganded cysteine is an active-site-proximal residue that is 13 Å from the NADP + molecule in a crystal structure of IDH1 (Extended Data Fig. 6a ). We confirmed that fragment ligands inhibited the activity of wild-type but not a C269S mutant of IDH1, and also blocked the R132H oncogenic mutant of IDH1 both in vitro and in cells (Extended Data Fig. 6b -k and Supplementary Discussion).
Encouraged by the cellular activity displayed by IDH1 ligands, we sought to more generally assess the capacity of fragment electrophiles to modify cysteines in situ. Cells were treated with ~ 20 representative members of the fragment library (50-200 μ M) for 2 h in situ and then harvested, lysed, and analysed by isoTOP-ABPP. The tested fragments showed a broad range of in situ reactivities that generally matched their respective reactivities in vitro, although some exceptional cases with greater or lesser reactivity in situ were noted (Extended Data Fig. 6l and Supplementary Table 1 ). These differences could reflect the impact of transport and/or metabolic pathways on the cellular concentrations of fragment electrophiles. A substantial fraction (64%) of the liganded cysteines identified in cell lysates were also sensitive to the Ratio (R) Fragment reactivity Letter reSeArCH same electrophilic fragments in cells (Extended Data Fig. 6m ). Four fragment-cysteine interactions were observed in situ, but not in lysates, including C182 of p53, a redox-regulated residue at the dimerization interface of the DNA-binding domain 23 (Extended Data Fig. 6n ). These liganded cysteines may require an intact cellular environment to preserve their interactions with fragment electrophiles. Several fragments targeted the catalytic cysteine nucleophile C360 of the protease caspase-8 (CASP8) in isoTOP-ABPP experiments performed in vitro and in situ (Extended Data Fig. 7a and Extended Data Table 1 ). Curiously, however, these fragments exhibited marginal to no inhibition of active CASP8 using either substrate or activity-based probe (Rho-DEVD-AOMK probe) assays (Extended Data Fig. 7b, c) . This initially puzzling outcome was explained when we discovered that the electrophilic fragments selectively labelled the inactive zymogen (pro-), but not active form of CASP8 (Fig. 4a, b , Extended Data Fig. 7b-l and Supplementary Discussion). We synthesized a clickable analogue of the most potent pro-CASP8 ligand 7 (61; Fig. 4a ) and found that this probe (25 μ M) strongly labelled pro-CASP8, but not a pro-CASP8 C360S mutant ( Fig. 4b and Extended Data Fig. 7i ), and directly modified C360 of CASP8 in Jurkat cell lysates (Extended Data  Table 1b ). Compound 7 (50 μ M) blocked labelling of pro-CASP8 by 61, but did not inhibit labelling of active CASP8 or other caspases by the Rho-DEVD-AOMK probe 24 (Fig. 4b and Extended Data Fig. 7k, l) . Conversely, the general caspase inhibitor Ac-DEVD-CHO (20 μ M) blocked Rho-DEVD-AOMK labelling of active CASP8 and other caspases, but not 61 labelling of pro-CASP8 ( Fig. 4b and Extended Data Fig. 7k, l) . Similar results were obtained in substrate assays, in which DEVD-CHO, but not 7, blocked CASP8 and CASP3 activity (Extended Data Fig. 7b ).
We next confirmed that 7, but not a structurally related inactive probe (62; Extended Data Fig. 7f , g, k, m and Supplementary Discussion) blocked Fas ligand (FasL)-, but not staurosporine (STS)-induced apoptosis in Jurkat cells (Extended Data Fig. 7n-p) . Chemical proteomic experiments revealed that 7 fully inhibited CASP8, as well as the related initiator caspase CASP10 (but not other caspases, including CASP2, 3, 6 and 9) in Jurkat cells (Fig. 4c , Extended Data Fig. 8a and Supplementary  Table 1 ). We confirmed that 7 blocked labelling of pro-CASP10 by 61 with an apparent half-maximum inhibitory concentration (IC 50 ) value of 4.5 μ M (Extended Data Fig. 8b-d ), but did not inhibit active CASP10 as measured by labelling with the Rho-DEVD-AOMK probe (Extended Data Fig. 7l ) or a substrate assay (Extended Data Fig. 8e ).
The respective functions of CASP8 and CASP10 in extrinsic apoptosis and other cellular processes remain poorly understood 25, 26 , in large part due to a lack of selective, non-peptidic, and cell-active inhibitors for these enzymes and the absence of animal models for CASP10 (which is not expressed in rodents). We therefore sought to address this challenge by improving the potency and selectivity of 7. Conversion of the 4-piperidino moiety to a 3-piperidino group and addition of a p-morpholino substituent to the benzoyl ring of 7 furnished compound 63 that was separated by chiral chromatography into its two purified enantiomers, 63-R ( Fig. 4c ) and 63-S (see Supplementary Information) , with 63-R showing substantially improved activity against CASP8 compared to compound 7 (63-R apparent IC 50 value of 0.7 μ M (95% confidence interval (CI), 0.5-0.8; Extended Data Fig. 8f-h) and negligible cross-reactivity with CASP10 (IC 50 value > 100 μ M; Extended Data Fig. 8c, d, f ). 63-S was much less active against CASP8 (apparent IC 50 value of 15 μ M; Extended Data Fig. 8g , h) and also inactive against CASP10 (Extended Data Fig. 8d ). With dual CASP8-CASP10 (7) and CASP8-selective (63-R) ligands in hand, we next set out to investigate the biological functions of these proteases.
We evaluated the effects of our caspase ligands in human T cells, in which both CASP8 and CASP10 are highly expressed (Extended Data Fig. 8i ) and their respective roles much debated 25, 26 , as well as in Jurkat cells, which are a commonly studied immortalized human T-cell line. We found that 63-R fully blocked FasL-induced apoptosis in Jurkat cells and did so with greater potency than 7 ( Fig. 4d and Extended Data Fig. 8j ) or 63-S (Extended Data Fig. 8k ). Similar results were obtained in HeLa cells, which express CASP8, but not CASP10 (Extended Data Fig. 8l ) 26 . In contrast to these cell line results, FasLinduced apoptosis in primary human T cells showed substantial resistance to 63-R at all tested concentrations and instead was completely inhibited by the dual CASP8/10 ligand 7 (Fig. 4d ). We confirmed by chemical proteomics with probe 61 that 7 blocked both CASP8 and CASP10, while 63-R inhibited CASP8, but not CASP10, in primary human T cells ( Supplementary Table 1 ) and Jurkat cells ( Fig. 4c and Supplementary Table 1 ). Consistent with these cell death results, 7, but not 63-R, prevented proteolytic processing of CASP3 and CASP10 in primary human T cells (Extended Data Fig. 8m ). Interestingly, the processing of both CASP8 and the initiator caspase substrate RIP kinase were also preferentially inhibited by 7 versus 63-R (Extended Data Fig. 8m ), indicating that CASP10 may contribute to these proteolytic events in T cells, as has been suggested by biochemical studies 27 . These data, taken together, support substantive functions for both CASP8 and CASP10 in primary human T cells and are consistent with genetic findings indicating that deleterious mutations in either CASP8 or CASP10 can lead to autoimmune syndromes in humans 28 .
By combining chemical proteomics with FBLD, we have found that the human proteome contains many ligandable cysteines. These cysteines were found in proteins not previously known to interact with small molecules, revealing that covalent chemistry can be used to expand the druggable content of the human proteome. Our results for 
pro-CASP8 and the results of others for K-Ras(G12C) 10, 11 indicate that it is possible to improve the potency and selectivity of covalent fragment hits for protein targets, although the optimization of covalent ligands for cysteines that reside in very shallow pockets may prove more challenging. Some covalent ligands may target cysteines at non-functional sites on proteins, and, in these cases, there is potential to convert the ligands into functional probes using emergent platforms for directing liganded proteins to degradation pathways in the cells 29, 30 . We envision that extensions of our chemical proteomic platform could be used to discover ligands that target other nucleophilic amino acids in proteins, thereby increasing the impact covalent chemistry will have on proteome-wide ligand and drug discovery.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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Preparation of human cancer cell line proteomes.
With the exception of MUM2C cells, which were provided by M. Hendrix, all cell lines were obtained from ATCC, tested negative for mycoplasma contamination, and were used without further authentication, maintaining a low passage number (< 10 passages). Cell lines were grown at 37 °C with 5% CO 2 . MDA-MB-231(ATCC: HTB-26), HeLa (ATCC: CCL-2) and HEK-293T (ATCC: CRL-3216) cells were grown in DMEM supplemented with 10% fetal bovine serum (FBS), penicillin, streptomycin and glutamine. Jurkat A3 (ATCC: CRL-2570), Ramos (ATCC: CRL-1596) and MUM2C cells were grown in RPMI-1640 medium supplemented with 10% FBS, penicillin and streptomycin. For in vitro labelling, cells were grown to 100% confluence for MDA-MB-231 cells or until cell density reached 1.5 million cells per ml for Ramos and Jurkat cells. Cells were washed with cold PBS, scraped with cold PBS and cell pellets were isolated by centrifugation (1,400g, 3 min, 4 °C) , and stored at − 80 °C until use. Cell pellets were lysed by sonication and fractionated (100,000g, 45 min) to yield soluble and membrane fractions, which were then adjusted to a final protein concentration of 1.5 mg ml −1 for proteomics experiments and 1 mg ml −1 for gel-based ABPP experiments. The soluble lysate was prepared fresh from frozen pellets directly before each experiment. Protein concentration was determined using the Bio-Rad DC protein assay kit. Proteomic sample preparation. IsoTOP-ABPP, stable isotope labelling by amino acids in cell culture (SILAC) and reductive dimethylation for stable isotope labelling (REDIME) samples were prepared and analysed as has been reported previously 12, [31] [32] [33] . For details see Supplementary Information. In vitro covalent fragment treatment. All compounds were made up as 50 mM stock solutions in DMSO and were used at a final concentration of 500 μ M. Owing to its low solubility in aqueous medium, fragment 4 was screened at a final concentration of 250 μ M. Soluble lysates were adjusted to 1.5 mg ml −1 and, for each profiling sample, 0.5 ml of lysate was treated with 5 μ l of the 50 mM compound stock solution or 5 μ l of DMSO. In situ covalent fragment treatment. For in situ labelling, MDA-MB-231 cells were grown to 95% confluence and Ramos cells were grown to 1 million cells per ml. The media in all samples was replaced with fresh media, containing 200 μ M of the indicated fragments and the cells were incubated at 37 °C for 2 h, washed with cold PBS, scraped into cold PBS and harvested by centrifugation (see earlier) .  Fragments 2, 3, 8, 9, 10, 12, 13, 14, 21, 27, 28, 29, 31, 33, 38, 45, 51 and 56 were screened at 200 μ M in situ. Fragments 4 and 11 were screened at 100 μ M in situ .  Fragments 2, 3, 8 and 20 were tested at 50 μ M in situ. Heat inactivation. For heat inactivation experiments, 500 μ l of MDA-MB-231 soluble proteome was denatured (95 °C, 10 min) and allowed to cool to ambient temperature. The denatured sample and corresponding non-denatured, native proteome (500 μ l) were then each labelled with 100 μ M iodoacetamide alkyne (IA-alkyne, 5 μ l of 10 mM stock in DMSO) and evaluated by isoTOP-ABPP. R value calculation and processing. The ratios of heavy/light for each unique peptide (DMSO/compound treated; isoTOP-ABPP ratios, R values) were quantified with in-house CIMAGE software 12, 13 , using default parameters (3 MS1 acquisitions per peak and signal to noise threshold set to 2.5). Site-specific engagement of electrophilic fragments was assessed by blockade of IA-alkyne probe labelling. For peptides that showed a ≥ 95% reduction in MS1 peak area from the fragment-treated proteome (light TEV tag) when compared to the DMSO-treated proteome (heavy TEV tag), a maximal ratio of 20 was assigned. Ratios for unique peptide entries are calculated for each experiment; overlapping peptides with the same modified cysteine (for example, different charge states, MudPIT chromatographic steps or tryptic termini) are grouped together and the median ratio is reported as the final ratio (R). The peptide ratios reported by CIMAGE were further filtered to ensure the removal or correction of low-quality ratios in each individual data set. The quality filters applied were the following: removal of half tryptic peptides; for ratios with high standard deviations from the median (90% of the median or above) the lowest ratio was taken instead of the median; removal of peptides with R = 20 and only a single MS2 event triggered during the elution of the parent ion; manual annotation of all the peptides with ratios of 20, removing any peptides with lowquality elution profiles that remained after the previous curation steps. Proteome reactivity values for individual fragments were computed as the percentage of the total quantified cysteine-containing peptides with R values ≥ 4 (defined as liganded cysteines) for each replicate experiment and the final proteome reactivity value was calculated as the mean for all replicate experiments for each fragment from both MDA-MB-231 and Ramos cellular proteomes. See Supplementary Information for additional details. Functional annotation of liganded cysteines. Custom Python scripts were used to compile functional annotations available in the UniProtKB/Swiss-Prot Protein Knowledge 34 database (release-2012_11). Relevant UniProt entries were mined for available functional annotations at the residue level, specifically for annotations regarding enzyme catalytic residues (active sites), disulfides (redox active and structural) and metal-binding sites. Liganded proteins were queried against the Drugbank database (v.4.2) 35 and fractionated into DrugBank and non-DrugBank proteins. Functional keywords assigned at the protein level were collected from the UniProt database and the DrugBank and non-DrugBank categories were further classified into protein functional classes. Previously collected cysteine reactivity data 12 were re-processed using ProLuCID as detailed in the Supplementary Information. Cysteines found in both the reactivity and ligandability data sets were sorted on the basis of their reactivity values (lower ratio indicates higher reactivity). The moving average of the percentage of total liganded cysteines within each reactivity bin (step-size 50) was taken. Custom Python scripts were developed to collect relevant NMR and X-ray structures from the RCSB Protein Data Bank (PDB) 36 . For proteins without available PDB structures, sequence alignments, performed with BLAST 37 to proteins deposited in the PDB, were used to identify structural homologues. For annotation of active-site and non-active cysteines, enzymes with structures in the PDB were manually inspected to evaluate the location of the cysteine. Cysteines were considered to reside in enzyme active sites if they were within 10 Å of an active-site ligand or residue(s). Cysteines outside of the 10 Å range were deemed non-active-site residues. Histograms of fragment hit-rates across high-coverage, ligandable cysteines, active-site and non-active site cysteines were calculated from the subset of ligandable cysteines quantified in ten or more separate experiments. For analyses of trends within the whole data, including histograms and heat maps, a cell-line merged data set was used in which data from the MDA-MB-231 experiments were taken first and the Ramos data were used if there were no data from MDA-MB-231 experiments for a particular fragment and cysteine. Heat maps were generated in R (v.3.1.3) using the heatmap.2 algorithm. Protein structures were rendered using PyMol 38 . Reactive cysteine docking. In silico fragment library containing all chloroacetamide and acrylamide fragments from Extended Data Fig. 1 was prepared using Open Babel library 39 with custom Python scripts. Fragments were modelled in their reactive form (that is, with explicit chloroacetamide and acrylamide warheads). Three-dimensional coordinates were generated from SMILES strings, calculating their protonation state at pH 7.4, and then minimizing them using MMF94 s forcefield (50K iterations steepest descent; 90K conjugate gradient); for chiral molecules with undefined configuration, all enantiomers were generated, resulting in 53 total fragments. For each protein, the UniProtKB accession number was used to filter the PDB 36 . Structures determined by X-ray crystallography were selected, privileging higher sequence coverage and structure resolution (see Extended Data Table 2 for selected PDB accessions). When no human structures were available, the closest homologous organism available was selected (for example, PRMT1: R. norvegicus). Protein structures were prepared following the standard AutoDock protocol. Waters, salts and crystallographic additives were removed; AutoDockTools 40 was used to add hydrogens, calculate Gasteiger-Marsili charges and generate PDBQT files. MSMS reduced surface method 41 was used to identify accessible cysteines. The protein volume was scanned using a probe radius of 1.5 Å; residues were considered accessible if they had at least one atom in contact with either external surfaces or internal cavities. The fragment library was docked independently on each accessible cysteine using AutoDock 4.2 (ref. 40) . A grid box of 24.4 × 24.4 × 24.4 Å was centred on the geometric centre of the residue; thiol hydrogen was removed from the side chain, which was modelled as flexible during the docking; the rest of the structure was kept rigid. A custom 13-7 interaction potential was defined between the nucleophile sulfur and the reactive carbon in the ligands. The equilibrium distance (r eq ) was set to the length of the C-S covalent bond (1.8 Å); the potential well depth (ε eq ) varied between 1.0 and 0.175 to model to the reactivity of the different ligands. For each fragment, potential well depth was determined by dividing its proteomic reactivity percentage by 20, and the value for iodoacetamide was approximated as the maximum (2.5) for reference. The potential was implemented by modifying the force field table of AutoDock. Fragments were docked with no constraints, generating 100 poses using the default GA settings. For each fragment, the best docking score pose was analysed: if the distance between the nucleophilic sulfur and the reactive carbon was ≤ 2.0 Å, the cysteine was considered covalently modified. If a residue was alkylated by at least one ligand, it was considered labelled. The docking score (that is, negative binding energy) was calculated based on the estimated interaction energy of each fragment in its docked pose. The docking score of the best alkylating fragment defined the labelling score. The residue with the best labelling score was considered the most probable to be labelled. CASP3 and CASP8 in vitro activity assays. CASP3 and 8 assays were conducted with CASP8 activity assay kit (BioVision, K112-100) and CASP3 activity assay kit (Invitrogen, EnzChek Caspase-3 Assay Kit), following the manufacturer's instructions. For further details see Supplementary Information.
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Primary human T-cell isolation and stimulation. All studies using samples from human volunteers follow protocols approved by The Scripps Research Institute institutional review board (protocol no. IRB-15-6682). Blood from healthy donors was obtained after informed consent and peripheral blood mononuclear cells (PBMCs) were purified over Ficoll-Hypaque gradients (Sigma-Aldrich). T cells were purified via negative selection with magnetic beads (EasySep, STEMCELL). The purified T cells were washed with sterile PBS and resuspended in RPMI-1640 supplemented with FBS, penicillin, streptomycin and glutamine (2 million cells per ml) and 200,000 cells per well were seeded on non-treated tissue culture, 96-well transparent plates that had been coated with anti-CD3 (1:200, BioXcell) and anti-CD28 (1:500, Biolegend) in PBS (100 μ l per well). The T cells were removed from stimulus after 3 days and cultured in complete RPMI-1640 supplemented with IL-2 (10 μ g ml −1 , eBioscience) for 3-4 additional days. Apoptosis assays in primary human T cells with CASP8 inhibitors. Primary human T cells were stimulated for 3 days with anti-CD3 and anti-CD28, and the cells were then washed and cultured in complete RPMI with IL-2 (10 μ g ml −1 ) for 4 additional days. For western blot analysis, 10 ml of stimulated primary human T cells (1.5 million cells per ml) in RPMI with IL-2 were then treated with the indicated compounds for 1 h before addition of FasL (1 μ l of 100 μ g μ l −1 stock solution of MegaFasLigand in water, final concentration = 10 ng ml −1 , Adipogen). After 3 h, cells were harvested by centrifugation, washed in PBS and lysed in cell lysis buffer (BioVision, 1067-100) with 1× complete protease inhibitor (Roche) and 40 μ g of each sample were separated by SDS-PAGE on 14% polyacrylamide gels. The gels were transferred to nitrocellulose membranes and were immunoblotted overnight with the indicated antibodies. For measurements of cell viability, in triplicate for each condition, 150,000 cells (100 μ l of 1.5 million cells per ml) were plated in 96-well optical-bottom plates. FasL was used at the same concentration indicated earlier with a 30 min pre-incubation with compounds at the indicated concentrations, followed by 4 h with FasL or DMSO. Twenty times compound stock solutions were made in RPMI immediately before use. Cell viability was measured with CellTiter-Glo Luminescent Cell Viability Assay (Promega) and was read on a Biotech Synergy 4 plate reader. Western blotting. For apoptosis studies, cell pellets were resuspended in cell lysis buffer from (BioVision, 1067-100) with 1× complete protease inhibitor (Roche) and allowed to incubate on ice for 30 min before centrifugation (10 min, 16,000g). For all other studies, cell pellets were resuspended in PBS and lysed with sonication before centrifugation (10 min, 16,000g). The proteins were then resolved by SDS-PAGE and transferred to nitrocellulose membranes, blocked with 5% milk in TBST and probed with the indicated antibodies. The primary antibodies and the dilutions used are as follows: anti-PARP (Cell Signaling, 9532, 1:1,000), anti-CASP3 (Cell Signaling, 9662, 1:1,000), anti-CASP8 (cleaved form, Cell Signaling, 9746, 1:1,000), anti-CASP8 (pro-form, Cell Signaling, 4970, 1:1,000), anti-IDH1 (Cell Signaling, 3997 s, 1:500), anti-actin (Cell Signaling, 3700, 1:3,000), anti-GAPDH (Santa Cruz, sc-32233, 1:2,000), anti-Flag (Sigma Aldrich, F1804, 1:3,000), anti-CASP10 (MBL, M059-3, 1:1,000), anti-RIPK (Cell Signaling, 3493S, 1:1,000). Blots were incubated with primary antibodies overnight at 4 °C with rocking and were then washed (3 × 5 min, TBST) and incubated with secondary antibodies (LICOR, IRDye 800CW or IRDye 800LT, 1:10,000) for 1 h at ambient temperature. Blots were further washed (3 × 5 min, TBST) and visualized on a LICOR Odyssey Scanner. The percentage cleavage was determined by quantifying the integrated optical intensity of the bands (n = 3 for STS and n = 2 for FasL), using ImageJ software 42 . For CASP8, the 43 and 41 kDa bands were quantified together. For CASP3, the 17 kDa subunit band was quantified. Statistical analysis. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. No statistical methods were used to predetermine sample size. Data are shown as mean ± standard error of the mean. P values were calculated using unpaired, two-tailed Student's t-test. P values of < 0.05 were considered significant. See also Supplementary Information. 
